SWBI Stock Analysis: Smith & Wesson Brands | NASDAQ
Aerospace & Defense | NASDAQ, USA | Market Cap: 669m USD | 12M Return: 87.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.1M
EPS Trend: -85.7%
Qual. Beats: 1
Rev. Trend: -51.1%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Smith & Wesson Brands, Inc. (NASDAQ: SWBI) is a U.S.-based designer, manufacturer, and global seller of firearms, offering handguns (revolvers and pistols), long guns (modern sporting rifles, pistol caliber carbines, and lever-action rifles), handcuffs, suppressors, and related accessories. The company also operates a contract manufacturing segment, providing forging, heat treating, machining, finishing, plating, plastic injection molding, assembly, and distribution services to third-party businesses.
Its products are sold to firearm enthusiasts, hunters, competitive shooters, home and personal protection buyers, law enforcement, and military agencies, distributed through independent dealers, retailers, in-store merchandising, direct-to-consumer channels, and range operations, supported by print, broadcast, digital, and social media advertising. Founded in 1852 and headquartered in Maryville, Tennessee, Smith & Wesson is classified in the Consumer Discretionary sector (Leisure Products sub-industry) and competes within a tightly regulated industry where finished firearms must move through Federal Firearms License (FFL) holders, making dealer relationships and distribution logistics central to the business model.
- Modern sporting rifle shipments drive long gun segment revenue
- Federal firearm regulation proposals trigger consumer pre-buy demand cycles
- Steel input costs and tariff exposure pressure manufacturing margins
| Net Income: 18.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 21.36 > 1.0 |
| NWC/Revenue: 31.70% < 20% (prev 44.37%; Δ -12.68% < -1%) |
| CFO/TA 0.22 > 3% & CFO 114.2m > Net Income 18.5m |
| Net Debt (53.8m) to EBITDA (60.5m): 0.89 < 3 |
| Current Ratio: 3.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.3m) vs 12m ago 1.95% < -2% |
| Gross Margin: 26.94% > 18% (prev 26.80%; Δ 0.13% > 0.5%) |
| Asset Turnover: 97.70% > 50% (prev 84.82%; Δ 12.88% > 0%) |
| Interest Coverage Ratio: 4.46 > 6 (EBIT TTM 29.2m / Interest Expense TTM 6.55m) |
| A: 0.32 (Total Current Assets 241.4m - Total Current Liabilities 75.4m) / Total Assets 512.8m |
| B: 0.73 (Retained Earnings 373.7m / Total Assets 512.8m) |
| C: 0.05 (EBIT TTM 29.2m / Avg Total Assets 536.2m) |
| D: 2.76 (Book Value of Equity 376.6m / Total Liabilities 136.2m) |
| Altman-Z'' = 7.77 = AAA |
| DSRI: 0.72 (Receivables 44.6m/55.9m, Revenue 523.8m/474.7m) |
| GMI: 1.00 (GM 26.80% / 26.94%) |
| AQI: 0.90 (AQ_t 0.06 / AQ_t-1 0.07) |
| SGI: 1.10 (Revenue 523.8m / 474.7m) |
| TATA: -0.19 (NI 18.5m - CFO 114.2m) / TA 512.8m) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of July 10, 2026, the stock is trading at USD 15.51 with a total of 493,729 shares traded. Over the past week, the price has changed by +3.40%, over one month by +5.36%, over three months by +7.97% and over the past year by +87.65%.
Current recommended Stop Loss: 14.20 (which is 8.4% or 1.9 ATR below the current price).
Smith & Wesson Brands has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy SWBI.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.3 | 11.2% |
P/E Trailing = 36.4634
P/E Forward = 11.7786
P/S = 1.2765
P/B = 1.7805
P/EG = 0.8406
Revenue TTM = 523.8m USD
EBIT TTM = 29.2m USD
EBITDA TTM = 60.5m USD
Long Term Debt = 19.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.86m USD (from shortTermDebt, last quarter)
Debt = 87.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 34.0m
Net Debt = 53.8m USD (calculated: Debt 87.2m - CCE 33.4m)
Enterprise Value = 722.5m USD (668.7m + Debt 87.2m - CCE 33.4m)
Interest Coverage Ratio = 4.46 (Ebit TTM 29.2m / Interest Expense TTM 6.55m)
EV/FCF = 8.00x (Enterprise Value 722.5m / FCF TTM 90.4m)
FCF Yield = 12.51% (FCF TTM 90.4m / Enterprise Value 722.5m)
FCF Margin = 17.25% (FCF TTM 90.4m / Revenue TTM 523.8m)
Net Margin = 3.53% (Net Income TTM 18.5m / Revenue TTM 523.8m)
Gross Margin = 26.94% ((Revenue TTM 523.8m - Cost of Revenue TTM 382.7m) / Revenue TTM)
Gross Margin QoQ = 29.76% (prev 26.23%)
Tobins Q-Ratio = 1.41 (Enterprise Value 722.5m / Total Assets 512.8m)
Interest Expense / Debt = 7.52% (Interest Expense 6.55m / Debt 87.2m)
Taxrate = 26.28% (6.59m / 25.1m)
NOPAT = 21.5m (EBIT 29.2m * (1 - 26.28%))
Current Ratio = 3.20 (Total Current Assets 241.4m / Total Current Liabilities 75.4m)
Debt / Equity = 0.23 (Debt 87.2m / totalStockholderEquity, last quarter 376.6m)
Debt / EBITDA = 0.89 (Net Debt 53.8m / EBITDA 60.5m)
Debt / FCF = 0.60 (Net Debt 53.8m / FCF TTM 90.4m)
Total Stockholder Equity = 366.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.45% (Net Income 18.5m / Total Assets 512.8m)
RoE = 5.04% (Net Income TTM 18.5m / Total Stockholder Equity 366.9m)
RoCE = 7.57% (EBIT 29.2m / Capital Employed (Equity 366.9m + L.T.Debt 19.1m))
RoIC = 5.22% (NOPAT 21.5m / Invested Capital 413.1m)
WACC = 7.80% (E(668.7m)/V(755.8m) * Re(8.09%) + D(87.2m)/V(755.8m) * Rd(7.52%) * (1-Tc(0.26)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -35.96 | Cagr: -0.74%
[DCF] Terminal Value 75.44% ; FCFF base≈90.4m ; Y1≈90.7m ; Y5≈96.1m
[DCF] Fair Price = 32.22 (EV 1.49b - Net Debt 53.8m = Equity 1.44b / Shares 44.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: -85.67 | EPS CAGR: -43.31% | SUE: 2.86 | # QB: 1
Revenue Correlation: -51.11 | Revenue CAGR: -2.55% | SUE: 2.78 | # QB: 2
EPS current Quarter (2026-07-31): EPS=-0.05 | Chg30d=+16.67% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-10-31): EPS=0.08 | Chg30d=+33.33% | Revisions=+0% | Analysts=1
EPS current Year (2027-04-30): EPS=0.47 | Chg30d=+42.42% | Revisions=+25% | GrowthEPS=+14.6% | GrowthRev=+5.2%
EPS next Year (2028-04-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+0.0%